共 50 条
- [31] Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared[J]. MOVEMENT DISORDERS, 2004, 19 (12) : 1522 - 1523Chaudhuri, KRDhawan, V
- [32] Risk of heart failure with dopamine agonists in patients with Parkinson's disease: differences between ergot and non-ergot derivatives[J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 11 - 11Montastruc, F.Moulis, F.Araujo, M.Chebane, L.Rascol, O.Montastruc, J. L.
- [33] Valvular heart disease in Parkinson's Disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography[J]. NEUROLOGY, 2006, 66 (05) : A48 - A48Junghanns, SFuhrmann, JSimonis, GOehlwein, CKoch, RStrasser, RHReichmann, HStorch, A
- [34] Dopamine agonists: their role in the treatment of Parkinson's disease[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (06): : 685 - 689Brooks, DJ
- [35] The safety of dopamine agonists in the treatment of Parkinson's disease[J]. EXPERT OPINION ON DRUG SAFETY, 2008, 7 (02) : 111 - 127Bonuccelli, UbaldoCeravolo, Roberto
- [36] Dopamine agonists in the treatment of early Parkinson's disease[J]. NEUROPROTECTION AND NEURODEGENERATION IN PARKINSON'S DISEASE, 2000, (71): : 33 - 37Rinne, UK
- [37] Pharmacology of dopamine agonists in the treatment of Parkinson's disease[J]. NEUROLOGY, 2002, 58 (04) : S1 - S8Jenner, P
- [38] The use of dopamine agonists in Parkinson's disease treatment[J]. ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2002, 102 (09): : 54 - 58Gekht, AB
- [39] New dopamine agonists for the treatment of Parkinson's disease[J]. AKTUELLE NEUROLOGIE, 1998, 25 (05) : 202 - 209Pogarell, OOertel, WH